REG - Hutchmed China Ltd - Appointment of Non–Executive Director

HUTCHMED (China)Announcement

16/05/2022 12:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220516:nRSP6322La&default-theme=true

RNS Number : 6322L  Hutchmed (China) Limited  16 May 2022

Appointment of Non-Executive Director

 

Hong Kong, Shanghai & Florham Park, NJ - Monday, May 16, 2022: HUTCHMED
(China) Limited ("HUTCHMED (https://www.hutch-med.com/) ") (Nasdaq/AIM:HCM;
HKEX:13) announces that Mr Lefei Sun has been appointed as a Non-Executive
Director with effect from May 16, 2022 and he will hold office until the next
annual general meeting ("AGM") of HUTCHMED when he will stand for re-election.
 

 

The Board of HUTCHMED considers that the appointment of Mr Sun will provide
significant benefits to HUTCHMED in view of his experience in capital markets,
M&A and business strategy. Aged 42, Mr Sun has been the Managing Director
and Head of China Healthcare for General Atlantic since 2018, in charge of
private equity investment and portfolio management in the healthcare and life
sciences sectors. General Atlantic owns approximately 3% of the ordinary
shares of HUTCHMED, through its affiliate General Atlantic Singapore HCM Pte.
Ltd.

 

Mr Simon To, Chairman of HUTCHMED, said, "On behalf of the Board, I would like
to extend a warm welcome to Mr Sun. I believe his appointment will further
strengthen our Board and we look forward to leveraging the wealth of
experience that he brings to the table from his career in life sciences and
healthcare investment."

 

Before joining General Atlantic, Mr Sun was the Founding Partner of Huatai
Healthcare Investment Fund, successfully leading the investment in Mindray
Medical, which is listed on Shenzhen Stock Exchange (SZSE:300760). Prior to
that, Mr Sun held various investment roles at Credit Suisse and OrbiMed, and a
strategy consultant role at McKinsey & Company, all in the healthcare
sector. Mr Sun holds a Bachelor of Science degree in Mathematics and Physics
from Tsinghua University. He also holds a Master of Arts degree in
neuroscience from the Johns Hopkins University.

 

Mr Sun also has relevant Board experience with both publicly listed and
private companies, having held the following directorships in the past five
years:

 

 Current Directorships:                  Previous Directorships in the last five years:
 Adagene Inc. (Nasdaq:ADAG)               Biotheus Inc.
 Adagene (Hong Kong) Limited              CANbridge Pharmaceuticals Inc. (HKEX:1228)
 Adagene (Suzhou) Ltd                     Huatai Healthcare Investment Fund
 Genesis MedTech Group Inc.               Ocumension Therapeutics Inc. (HKEX:1477)
 Hong Kong Asia Medical Holding Limited

 

Under the terms of the appointment of Mr Sun as a non-executive director of
the Company until the next AGM, he has agreed that he will not receive any fee
for his service and that his appointment will be renewed for successive
12-month periods, unless he is not re-elected at the next AGM or his
appointment is otherwise terminated earlier by either party in writing.

 

Appointment Regulatory Disclosures

Save for the appointments listed above, Mr Sun has held no other directorships
during the period of five years prior to his appointment as a director of
HUTCHMED. Save for his role with General Atlantic, Mr Sun does not have any
relationship with any Directors, senior management or substantial or
controlling shareholders of HUTCHMED. Mr Sun does not have any interest in the
ordinary shares of HUTCHMED within the meaning of Part XV of the Securities
and Futures Ordinance (Cap.571 of the Laws of Hong Kong).

 

Save for the information disclosed above, there is no other information in
relation to Mr Sun that is required to be disclosed pursuant to Rule 17 and
Schedule 2(g) of the AIM Rules for Companies or Rule 13.51(2) of the Rules
Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited
and there are no other matters concerning the appointment of Mr Sun that are
required to be brought to the attention of the shareholders of HUTCHMED.

 

About HUTCHMED

HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage,
biopharma-ceutical company. It is committed to the discovery and global
develop-ment and commercial-ization of targeted therapies and immuno-therapies
for the treatment of cancer and immuno-logical diseases. It has more than
4,600 personnel across all its companies, at the center of which is a team of
about 1,700 in oncology/immunology. Since inception it has advanced 12 cancer
drug candidates from in-house discovery into clinical studies around the
world, with its first three oncology drugs now approved and marketed in China.
For more information, please visit: www.hutch-med.com
(https://www.hutch-med.com/) or follow us on LinkedIn
(https://www.linkedin.com/company/hutchmed/) .

 

 

CONTACTS
 Investor Enquiries
 Mark Lee, Senior Vice President    +852 2121 8200
 Annie Cheng, Vice President        +1 (973) 567 3786

 Media Enquiries
 Americas - Brad Miles,             +1 (917) 570 7340 (Mobile)

Solebury Trout
bmiles@troutgroup.com
 Europe - Ben Atwell / Alex Shaw,   +44 20 3727 1030 / +44 7771 913 902 (Mobile) /

FTI Consulting                    +44 7779 545 055 (Mobile)
                                    HUTCHMED@fticonsulting.com
 Asia - Zhou Yi,                    +852 9783 6894 (Mobile)

Brunswick                         HUTCHMED@brunswickgroup.com

 Nominated Advisor
 Atholl Tweedie / Freddy Crossley,  +44 (20) 7886 2500

Panmure Gordon (UK) Limited

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBQLFFLELEBBF